Cover Image

Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus

Infections with Herpes simplex virus (HSV)-1 or -2 usually present as mild chronic recurrent disease, however in rare cases can result in life-threatening conditions with a large spectrum of pathology. Monoclonal antibody therapy has great potential especially to treat infections with virus resistan...

Full description

Saved in:
Bibliographic Details
Main Authors: Seyfizadeh, Narges (Author) , Kalbermatter, David (Author) , Imhof, Thomas (Author) , Ries, Moritz (Author) , Müller, Christian (Author) , Jenner, Leonie (Author) , Blumenschein, Elisabeth (Author) , Yendrzheyevskiy, Alexandra (Author) , Grün, Frank (Author) , Moog, Kevin (Author) , Eckert, Daniel (Author) , Engel, Ronja (Author) , Diebolder, Philipp (Author) , Chami, Mohamed (Author) , Krauß, Jürgen (Author) , Schaller, Torsten (Author) , Arndt, Michaela (Author)
Format: Article (Journal)
Language:English
Published: 2024
In: Journal of biomedical science
Year: 2024, Volume: 31, Pages: 1-22$p22
ISSN:1423-0127
DOI:10.1186/s12929-024-01045-2
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12929-024-01045-2
Verlag, lizenzpflichtig, Volltext: https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-024-01045-2
Get full text
Author Notes:Narges Seyfizadeh, David Kalbermatter, Thomas Imhof, Moritz Ries, Christian Müller, Leonie Jenner, Elisabeth Blumenschein, Alexandra Yendrzheyevskiy, Frank Grün, Kevin Moog, Daniel Eckert, Ronja Engel, Philipp Diebolder, Mohamed Chami, Jürgen Krauss, Torsten Schaller and Michaela Arndt
Description
Summary:Infections with Herpes simplex virus (HSV)-1 or -2 usually present as mild chronic recurrent disease, however in rare cases can result in life-threatening conditions with a large spectrum of pathology. Monoclonal antibody therapy has great potential especially to treat infections with virus resistant to standard therapies. HDIT101, a humanized IgG targeting HSV-1/2 gB was previously investigated in phase 2 clinical trials. The aim of this study was to develop a next-generation therapy by combining different antiviral monoclonal antibodies.
Item Description:Veröffentlicht: 28 May 2024
Gesehen am 11.06.2025
Physical Description:Online Resource
ISSN:1423-0127
DOI:10.1186/s12929-024-01045-2

Similar Items